Tempus AI Secures Enterprise-Wide Access Deal at Gilead Sciences 🔗

Tempus AI has significantly expanded its partnership with Gilead Sciences, granting the company enterprise-wide access to its Lens platform and anonymised oncology datasets across multiple cancer types. The collaboration now extends to trial design, biomarker strategy, real-world evidence generation, and clinical data analytics embedded across Gilead's full oncology R&D portfolio — broadening a previous agreement that had been limited to specific applications. Tempus reported 111.5% growth in its Diagnostics division in 2025, with its Data and Applications division generating $100.4 million in Q4 alone, up 25% year-on-year. The Gilead deal follows a similar enterprise-level adoption by Daiichi Sankyo the prior week. Two top-20 pharma companies converting to platform-scale access in consecutive weeks points toward a systematic adoption pattern rather than isolated deal activity.

Caris Life Sciences Launches Multimodal AI to Guide Chemotherapy Decisions in Lung Cancer 🔗

Caris Life Sciences has unveiled a new AI-driven molecular insight tool through its CodeAI platform, designed to determine which non-small cell lung cancer patients will benefit from adding chemotherapy to immunotherapy — and which will not. The tool integrates whole exome sequencing and whole transcriptome sequencing data to categorise patients into risk groups and predict individual chemotherapy response. NSCLC is the most prevalent form of lung cancer, and the chemotherapy-plus-immunotherapy decision has historically rested on clinical assessment rather than tumour biology. Caris is moving that decision onto a molecular evidence base, with direct implications for both patient toxicity outcomes and treatment cost.

PathAI and MedStar Health Deploy FDA-Cleared Digital Pathology Platform Across Clinical Network 🔗

PathAI and MedStar Health have launched a multi-year partnership to implement the AISight Dx Digital Pathology Platform across MedStar's laboratory network. AISight Dx is FDA-cleared for primary diagnostic use and integrates slide management, AI-assisted review, and clinical workflow tools across a network serving over 40 pathologists. The deployment includes PathAI's ArtifactDetect algorithm alongside TumorDetect, currently designated for research use. The partnership extends an existing collaboration through PathAI's Early Access Program and is designed to lay the groundwork for ongoing research through MedStar's Precision Pathology Network.

Veeva Integrates RegASK for Real-Time Regulatory Intelligence 🔗

Veeva Systems has announced a partnership with RegASK to embed predictive regulatory intelligence into its Regulatory Information Management platform. The integration delivers near-real-time updates on global regulatory changes, enabling pharma companies to manage compliance proactively rather than reactively. Veeva describes the move as part of a broader shift: transitioning the platform from a system of record to a system of action.

The Signal: Two weeks after acquiring Ostro for $100 million, Veeva is now absorbing the regulatory intelligence layer through partnership. Both moves follow the same logic: pull the compliance and intelligence functions that pharma companies currently assemble from multiple vendors inside the Veeva platform. Point solutions in regulatory AI are operating in a market that the dominant commercial platform is actively consolidating around them. Each capability Veeva absorbs — whether through acquisition or integration — raises the threshold a competing vendor must clear to remain independently viable.

Beacon Reaches $132 Million in Total Capital to Scale AI Neurodiagnostics 🔗
Beacon, a neurotechnology company backed by Google Ventures and Catalio Capital Management, has closed a $97 million Series B upsizing on April 6, bringing total cumulative funding to $132 million. The device monitors neural signals during sleep to assist in diagnosing conditions including narcolepsy and epilepsy, generating objective brain function metrics for pharmaceutical partners. Bristol Myers Squibb and Novartis have already adopted the platform. An expanded collaboration with Takeda is focused specifically on at-home sleep monitoring to accelerate the identification of sleep biomarkers for clinical trials.

The Signal: Neurological diagnostics is following the same trajectory that oncology diagnostics took two years ago — wearable, continuously measured, AI-interpreted, and already embedded in major pharma development programs as a source of trial-grade evidence. The involvement of three top-tier pharma companies as early adopters, alongside Google Ventures' backing, makes this more than a hardware fundraise. Beacon is building the evidence generation infrastructure for a new category of neuroscience-adjacent clinical research, and the pharma partnerships suggest the category already has a market.

Guideways Launches AI Agents to Navigate the FDA Medical Device Approval Process 🔗

Guideways has launched a platform deploying three specialised AI agents — FDA Sherpa, FDA Reviewer, and FDA Researcher — to guide medical device teams through regulatory strategy development, submission review, and standards compliance. The platform draws on a curated database of over 150,000 FDA documents. Regulatory processes currently consume up to 75% of MedTech development budgets and delay market entry by between 31 and 66 months.

The Signal: Agentic AI is now targeting the regulatory process itself — not the science behind devices, but the institutional knowledge required to move them through the approval system. The same pattern reshaping pharma compliance (Veeva + RegASK, Domino's agentic lifecycle release) is arriving in MedTech. If AI can compress a 31-to-66-month approval window by any meaningful margin, it may represent one of the highest-return applications of the technology in the sector. Guideways is early. The category it is building will not stay small.